APA citiranje

Weber, J., Grob, J., Margolin, K. A., Ascierto, P. A., Sznol, M., Ott, P. A., . . . Hodi, F. S. (2015). A Phase III study (CheckMate 238) of adjuvant immunotherapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage IIIb/c or stage IV melanoma (MEL) in patients (pts) at high risk for recurrence. J Immunother Cancer.

Citação norma Chicago

Weber, Jeffrey, et al. "A Phase III Study (CheckMate 238) of Adjuvant Immunotherapy With Nivolumab (NIVO) Versus Ipilimumab (IPI) After Complete Resection of Stage IIIb/c or Stage IV Melanoma (MEL) in Patients (pts) At High Risk for Recurrence." J Immunother Cancer 2015.

MLA citiranje

Weber, Jeffrey, et al. "A Phase III Study (CheckMate 238) of Adjuvant Immunotherapy With Nivolumab (NIVO) Versus Ipilimumab (IPI) After Complete Resection of Stage IIIb/c or Stage IV Melanoma (MEL) in Patients (pts) At High Risk for Recurrence." J Immunother Cancer 2015.